We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Name | Symbol | Market | Type |
|---|---|---|---|
| Unilever PLC | NYSE:UL | NYSE | Depository Receipt |
| Price Change | % Change | Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| -0.48 | -0.88% | 54.00 | 412 | 09:27:36 |
From May 2021 to May 2024
By Anthony O. Goriainoff
Arecor Therapeutics PLC said Monday that its insulin candidate for diabetes, AT278, met all primary and secondary endpoints with positive headline results from the Phase 1 clinical trial.
The London-listed biopharmaceutical company--backed by Unilever PLC--said AT278 had the potential to significantly improve post prandial glucose control and reduce the injection volume and/or number of daily injections of people with diabetes who have a high daily insulin need.
"These positive data for AT278, the second product in our diabetes franchise, follow the earlier positive results from the Phase I clinical trial of AT247... Together they position Arecor with a unique combination of ultra-concentrated and ultra-rapid insulin candidates offering the potential to meet the broad needs of patients across the growing diabetes market," Chief Executive Sarah Howell said.
Write to Anthony O. Goriainoff at anthony.orunagoriainoff@dowjones.com
(END) Dow Jones Newswires
September 20, 2021 03:16 ET (07:16 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
1 Year Unilever Chart |
1 Month Unilever Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
